Lunit said it will participate in the upcoming 2025 European Congress of Radiology (ECR 2025) in Vienna, Austria, from Feb. 26 to March 2.

ECR, alongside the Radiological Society of North America (RSNA) conference, is one of the most prestigious radiology congresses worldwide. This year’s event, themed “Planet Radiology,” is expected to attract over 10,000 radiologists, healthcare professionals, researchers, and industry leaders from around the world. Lunit has been participating in ECR annually since 2020, consistently unveiling research achievements.

Together with its subsidiary, Volpara Health, Lunit will present an unprecedented 15 research abstracts at the event — the highest number in ECR history. Among the 15 research abstracts accepted for ECR 2025, 13 have been selected for oral presentation.

Lunit's participation will focus on addressing key challenges in breast cancer diagnosis, particularly tackling the global shortage of radiologists and improving early cancer detection and diagnostic accuracy through innovative AI solutions.

The company will introduce several pivotal studies, including the feasibility of AI replacing a second radiologist in double-reading mammography environments, analysis of AI utilization in early breast cancer detection, the impact of mammographic image quality on AI interpretation accuracy, and breast characteristics of patients diagnosed during routine screening versus those diagnosed between screenings.

In addition to research presentations, Lunit and Volpara will operate an exclusive exhibition booth at the conference, providing hands-on demonstrations of their solutions and engaging in business activities aimed at expanding their footprint in the European market.

“We are honored to have a record-high number of research abstracts and oral presentations selected at ECR, the largest radiology congress in Europe,” Lunit CEO Brandon Suh said. “This event serves as a crucial platform to showcase our innovative technology and research capabilities in the global cancer diagnostics field.”

The company will continue to drive forward research that delivers tangible value to the medical community, Suh added.